![Christina Rossi](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christina Rossi
Directeur/Membre du Conseil chez
CG ONCOLOGY, INC.
Fortune : - $ au 31/08/2026
Profil
Christina Rossi is currently Director at CG Oncology, Inc. since 2025.
Former roles include Independent Director at Xilio Therapeutics, Inc. from 2021 to 2026; Chief Operating Officer at Blueprint Medicines Corp.
from 2022 to 2025; Head-Multiple Sclerosis Business Unit at Genzyme Corp.
from 2012 to 2018; Head-Multiple Sclerosis Business North America at Genzyme Therapeutics Ltd. from 2016 to 2018; and Head-Commercial Strategy at Eidetica Biopharma GmbH from 2005 to 2010.
Education includes an undergraduate degree from Duke University in 1997 and an MBA from Harvard Business School in 2003.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CG ONCOLOGY, INC. -.--% | 04/06/2026 | 0 ( -.--% ) | - $ | 31/08/2026 |
Postes actifs de Christina Rossi
| Sociétés | Poste | Début |
|---|---|---|
| CG ONCOLOGY, INC. | Directeur/Membre du Conseil | 24/11/2025 |
Anciens postes connus de Christina Rossi
| Sociétés | Poste | Fin |
|---|---|---|
| XILIO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 15/04/2026 |
| BLUEPRINT MEDICINES CORPORATION | Directeur des opérations | 01/01/2025 |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | 01/10/2018 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Corporate Officer/Principal | 01/10/2018 |
Eidetica Biopharma GmbH
 Eidetica Biopharma GmbH Pharmaceuticals: MajorHealth Technology Develops and manufactures biopharmaceutical drugs | Corporate Officer/Principal | 01/01/2010 |
Formation de Christina Rossi
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
98
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
Blueprint Medicines Corp.
 Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
CG Oncology, Inc.
 CG Oncology, Inc. BiotechnologyHealth Technology Operates as a late-stage clinical biopharmaceutical company focused on developing and commercializing backbone bladder-sparing therapeutic | Health Technology |
Eidetica Biopharma GmbH
Eidetica Biopharma GmbH Pharmaceuticals: MajorHealth Technology Develops and manufactures biopharmaceutical drugs | Health Technology |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xilio Therapeutics, Inc.
 Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | Health Technology |
